Evidence map›Paper›PMID 41694309›Full record

ArticleFrontiers in cardiovascular medicine2026

Safety and feasibility of the treatment of calcified

Alma Räsänen, Antti Eranti, Tuomas T Rissanen

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alma RäsänenHeart Center, North Karelia Central Hospital, Joensuu, Finland.
Antti ErantiHeart Center, North Karelia Central Hospital, Joensuu, Finland.
Tuomas T RissanenHeart Center, North Karelia Central Hospital, Joensuu, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Percutaneous coronary intervention (PCI) of calcified lesions using stenting may lead to stent malapposition and stent underexpansion. The combination of intravascular lithotripsy (IVL) followed by drug-coated balloon (DCB) treatment may help overcome this limitation. The aim of this single-center, retrospective, registry-based observational study was to assess the efficacy and safety of plaque modification using IVL followed by DCB-only treatment in patients with severely calcified lesions. Methods: Severely calcified Results: There were no acute vessel closures or perioperative myocardial infarctions. During 12-month follow-up, the primary end point occurred in 15% ( Conclusions: PCI using IVL in combination with an application of paclitaxel-DCB strategy was feasible in the treatment of severely calcified coronary artery lesions in this cohort. This novel approach may be particularly advantageous for patents at high risk of bleeding, although further studies are needed to confirm this potential benefit.

Indexed as

bleeding riskcalcified lesionsdrug-coated balloondrug-eluting balloonlithotripsymyocardial infarction

Identifiers

PMID41694309
PMCPMC12902940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.